A Phase 1, First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PVT401 Following Randomized, Double-blind, Placebo-controlled Single and Multiple Ascending Doses in Healthy Subjects
Latest Information Update: 03 Mar 2026
At a glance
- Drugs PVT 401 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; First in man
- Sponsors Parvus Therapeutics
Most Recent Events
- 03 Mar 2026 New trial record